A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA).
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2018
At a glance
- Drugs SHP 647 (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Acronyms AIDA
- Sponsors Shire
- 16 Mar 2018 Status changed from not yet recruiting to recruiting.
- 16 Mar 2018 Planned number of patients changed from 1114 to 2453.
- 16 Mar 2018 Planned End Date changed from 11 Feb 2025 to 3 Jun 2025.